Profile

Arthur W. Blackstock Jr, M.D.Wake Forest Baptist Health

Doctor Rating

4.8 out of 5

74 Ratings
14 Comments
 

Arthur W. Blackstock Jr, M.D.

Program Director,
Chair,
Professor,




Clinical Interests

Lung Cancer, Pancreatic Cancer

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-3600
Department: 336-713-3600

Email: ablackst@wakehealth.edu

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.A., Wake Forest University, 1985
  • M.D., University of North Carolina-Chapel Hill, 1989
  • Internship, Pitt County Mem Hosp, 1990
  • Internship, Univ No Carolina Affil Hosps, 1994
  • Fellowship, North Carolina Baptist Hospita, 1994

NPI Number

  • 1356323307
Arthur W. Blackstock Jr, M.D.

Doctor Rating

4.8 out of 5

74 Ratings
14 Comments
 

Arthur W. Blackstock Jr, M.D.

Program Director, Comprehensive Cancer Center
Chair, Radiation Oncology
Professor, Radiation Oncology
Brain Tumor Center of Excellence
Comprehensive Cancer Center
Maya Angelou Center for Health Equity
Cancer Biology

Research Interests

cancer/oncogenesis

Contact Information

Academic: 336-713-3600 | Department: 336-713-3600

Email: ablackst@wakehealth.edu

Media Medical Expert »

Recent Publications

Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock DN, Blackstock AW, Hinson WH, Munley MT, Petty WJ, Urbanic JJ. Is a clinical target volume (CTV) necessary in the treatment of lung cancer in the modern era combining 4-D imaging and image-guided radiotherapy (IGRT)?. Cureus. 2016;8(1):e466.

Onyeuku NE, Ayala-Peacock DN, Russo SM, Blackstock AW. The multidisciplinary approach to the treatment of rectal cancer: 2015 update. Expert Rev Gastroenterol Hepatol. 2015;9(4):507-517.

Daroui P, Jabbour SK, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Goodman KA, Hong TS, Jones WE III, Kaur H, Konski AA, Koong AC, Kumar R, Pawlik TM, Small W Jr, Thomas CR Jr, Suh WW. ACR Appropriateness Criteria resectable stomach cancer. Oncology (Williston Park). 2015;29(8):595-603.

Wang A, Sanoff HK, McRee AJ, O'Neil BH, Calvo BF, Hennessy MG, Murphy C, Tynan TM, Blackstock AW, Garmey EG, Tepper JE. Phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer [abstract]. J Clin Oncol. 2015;33(15 Suppl):TPS3629.

Russo S, Blackstock AW, Herman JM, Abdel-Wahab M, Azad N, Das P, Goodman KA, Hong TS, Jabbour SK, Jones WE III, Konski AA, Koong AC, Kumar R, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Suh WW. ACR Appropriateness Criteria local excision in early stage rectal cancer. Am J Clin Oncol. 2015;38(5):520-525.

Kilburn JM, Soike MH, Lucas JT, Ayala-Peacock D, Blackstock W, Isom S, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ. Image guided radiation therapy may result in improved local control in locally advanced lung cancer patients. Pract Radiat Oncol. 2015;():.

Hong TS, Petz JL, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Goodman KA, Jabbour SK, Jones WE III, Konski AA, Koong AC, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Zook J, Suh WW. ACR appropriateness criteria-anal cancer. Gastrointest Cancer Res. 2014;7(1):4-14.

Kilburn JM, Lester SC, Lucas JT Jr, Soike MH, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ. Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer. J Thorac Oncol. 2014;9(4):572-576.

Kilburn JM, Kuremsky JG, Blackstock AW, Munley MT, Kearns WT, Hinson WH, Lovato JF, Miller AA, Petty WJ, Urbanic JJ. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol. 2014;110(3):505-510.

Lucas JT Jr, Kuremsky JG, Soike M, Hinson WW, Kearns WT, Hampton CJ, Blackstock AW, Urbanic J. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC). Lung Cancer. 2014;85(1):59-65.

Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock D, Kuremsy JG, Blackstock A, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ. Which lung tumors shrink during fractionated radiation and how does this influence outcome?: Appropriately selecting tumor and treatment characteristics for adaptive radiation therapy protocols [abstract]. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S641-S642.

Lester SC, Kilburn JM, Lucas JT, Soike MH, Blackstock AW, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ. An evaluation of toxicity using accumulated total dose based on EQD2 for thoracic reirradiation incorporating at least 1 course of SBRT [abstract]. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S640-S641.

Goodman KA, Milgrom SA, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Hong TS, Jabbour SK, Jones WE III, Konski AA, Koong AC, Kumar R, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Suh WW. ACR appropriateness criteria rectal cancer: metastatic disease at presentation. Oncology (Williston Park). 2014;28(10):867-+.

Almeida C, Nagarajan D, Tian J, Leal SW, Wheeler K, Munley M, Blackstock W, Zhao W. The role of alveolar epithelium in radiation-induced lung injury. PLoS One. 2013;8(1):e53628.

Monjazeb AM, Blackstock AW. The impact of multimodality therapy of distal esophageal and gastroesophageal junction adenocarcinomas on treatment-related toxicity and complications. Semin Radiat Oncol. 2013;23(1):60-73.

Raftery L, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BH. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma. Am J Clin Oncol. 2013;36(3):250-253.

Ayala-Peacock DN, Blackstock AW, Kearns WT, Hinson WH, Munley MT, Miller AA, Petty WJ, Urbanic JJ. Stereotactic body radiation therapy (SBRT) and image guided accelerated hypofractionated radiation therapy (IGAHRT) for the treatment of oligometastatic cancers [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S567-S568.

Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock D, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Urbanic JJ. Is a clinical target volume (CTV) necessary in treatment of thoracic malignancies treated in the modern era combining 4-D imaging and image guided radiation therapy (IGRT)? [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S549.

Kilburn JM, Lester SC, Lucas JT, Blackstock AW, Kearns WT, Hinson WH, Munley MT, Miller AA, Petty WJ, Urbanic JJ. Multiple courses of thoracic radiation therapy (XRT) using stereotactic body radiation therapy (SBRT) as the first or second course of treatment for tumors outside the original high-dose region [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S36.

Lester SC, Kilburn JM, Lucas JT, Munley MT, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Urbanic JJ. Salvage radiation for mediastinal relapse after treatment with accelerated hypofractionated radiation therapy (AHRT) or stereotactic body radiation therapy (SBRT) for stage I/II NSCLC [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S543-S544.

Russo S, Blackstock AW Jr. The 'watch-and-wait' approach for rectal cancer: are outcomes improved with more limited T stage and routine use of MRI for staging? [comment]. Oncology (Williston Park). 2013;27(10):976-977.

Soike M, Kilburn JM, Lucas JT, Ayala-Peacock D, Blackstock AW, Kearns WT, Hinson WH, Miller AT [sic] [Miller AA], Petty WJ, Urbanic JJ. Image guided radiation therapy results in mproved local control in lung cancer patients treated with fractionated radiation therapy for stage IIB-IIIB disease [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S547-S548.

Ayala-Peacock DN, Onyeuku N, Thomas AJ, Garg P, Blackstock AW. A pilot 11C-choline PET/CT imaging study investigating the ability to detect occult metastatic osseous disease in newly diagnosed high-risk prostate adenocarcinoma. Pract Radiat Oncol. 2013;3(2 Suppl 1):S27.

Ayala-Peacock DN, Thomas AJ, Smith H, Garg P, Blackstock AW. A pilot 11C-choline PET-CT imaging study in patients with locally advanced esophageal cancer. Pract Radiat Oncol. 2013;3(2 Suppl 1):S23.

Weaver KE, Danhauer SC, Tooze JA, Blackstock AW, Spangler J, Thomas L, Sutfin EL. Smoking cessation counseling beliefs and behaviors of outpatient oncology providers. Oncologist. 2012;17(3):455-462.

Kimple RJ, Russo S, Monjazeb A, Blackstock AW. The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Rev Anticancer Ther. 2012;12(4):469-480.

Jones WE III, Thomas CR Jr, Herman JM, Abdel-Wahab M, Azad N, Blackstock W, Das P, Goodman KA, Hong TS, Jabbour SK, Konski AA, Koong AC, Rodriguez-Bigas M, Small W Jr, Zook J, Suh WW. ACR Appropriateness Criteria: resectable rectal cancer. Radiat Oncol. 2012;7():161.

Socinski MA, Stinchcombe TE, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Khandani A, Morris DE. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. J Clin Oncol. 2012;30(32):3953-3959.

Blackstock A, Lally B, Isom S, Paskett E. Impact of marital status and race on survival for patients with colon cancer: an analysis of data from the Surveillance, Epidemiology, and End-Results (SEER) Program [abstract]. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S539.

Kilburn JM, Kuremsky JG, Blackstock AW, Kearns WT, Hampton CJ, Hinson WH, Miller AA, Petty WJ, Urbanic JJ. Thoracic reirradiation in patients with stereotactic body radiation therapy (SBRT) as first or second course of treatment [abstract]. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S604.

Kuremsky JG, Petty WJ, Miller A, Hinson WH, Hampton CJ, Blackstock AW, Urbanic JJ. Hypofractionated radiation therapy for stage I and II non-small cell lung cancer [abstract]. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S153-S154.

Urbanic JJ, Soike M, Hampton CJ, Lucas J, Hinson W, Kearns W, Blackstock AW. Long-term follow-up and patterns of failure for patients with medically inoperable stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) [abstract]. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S609.

Kilburn KM, Kuremsky JG, Blackstock AW, Kearns WT, Hampton CJ, Hinson WH, Miller AA, Petty WJ, Urbanic JJ. Thoracic re-irradiation in patients with stereotactic body radiotherapy (SBRT) as first or second course of treatment [abstract]. J Thorac Oncol. 2012;7(9 Suppl 4):S253-S254.

Kuremsky JG, Petty WJ, Miller A, HInson WH, Hampton CJ, Blackstock AW, Urbanic JJ. Hypofractionated radiotherapy for stage I and II non-small cell lung cancer [abstract]. J Thorac Oncol. 2012;7(9 Suppl 4):S230.

Lucas JT, Kuremsky JG, Soike M, Hinson W, Kearns WT, Hampton CJ, Blackstock AW, Urbanic JJ. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for stage 1 & 2 non-small cell lung cancer (NSCLC) [abstract]. J Thorac Oncol. 2012;7(9 Suppl 4):S228.

Urbanic JJ, Soike M, Hampton CJ, Lucas J, Hinson W, Kearns W, Blackstock AW. Long-term follow-up and patterns of failure for patients with medically inoperable Stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT) [abstract]. J Thorac Oncol. 2012;7(9 suppl 4):S288.

Monjazeb AM, Blackstock AW. Was F-18 fluorodeoxyglucose positron emission tomography complete response after chemoradiotherapy defined as standardized uptake value(max-1 hour) less than or equal to 3 complete? [reply to letter]. J Clin Oncol. 2011;29(9):E249-E250.

Stinchcombe T, Socinski MA, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Morris DE. Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2011;29(Suppl):abstr 7016.

Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : Cancer and Leukemia Group B (CALGB) 80003. Cancer. 2011;117(12):2620-2628.

Yang X, Walton W, Cook DN, Hua X, Tilley S, Haskell CA, Horuk R, Blackstock AW, Kirby SL. The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45(1):127-135.

Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011;103(20):1498-1506.

Attia A, Vern-Gross T, Garg PK, Garg S, Thomas A, Smith H, Monjazeb A, Blackstock AW. The utility of 11C-choline positron emission tomography computerized tomography (PET-CT) for staging locally advanced esophageal cancer [abstract]. Int J Radiat Oncol Biol Phys. 2011;81(2 Suppl):S314.

Salama JK, Stinchcombe TE, Gu L, Wang X, Morano K, Bogart JA, Crawford JC, Socinski MA, Blackstock AW, Vokes EE. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 GY) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy:. Int J Radiat Oncol Biol Phys. 2011;81(4):e269-e274.

Center B, Petty WJ, Ayala D, Hinson WH, Lovato J, Capellari J [sic] [Cappellari J], Oaks T, Miller AA, Blackstock AW. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol. 2010;5(1):69-74.

Bogart JA, Hodgson L, Seagren SL, Blackstock AW, Wang X, Lenox R, Turrisi AT III, Reilly J, Gajra A, Vokes EE, et al. Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. J Clin Oncol. 2010;28(2):202-206.

Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW. Outcomes of patients with esophageal cancer staged with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?. J Clin Oncol. 2010;28(31):4714-4721.

Monjazeb AM, Riedlinger G, Isom S, Aklilu M, Geisinger KR, Mishra G, Levine EA, Blackstock AW. Radiotherapy for esophageal cancer: does dose affect outcomes? [abstract]. Int J Radiat Oncol Biol Phys. 2010;78(3 Suppl):S307.

Lally BE, Geiger AM, Urbanic JJ, Butler JM, Wentworth S, Perry MC, Wilson LD, Horton JK, Detterbeck FC, Miller AA, Blackstock AW, et al. Trends in the outcomes for patients with limited stage small cell lung cancer: an analysis of the Surveillance, Epidemiology, and End Results database. Lung Cancer. 2009;64(2):226-231.

Blackstock AW, Aklilu M, Lovato J, Degrass L, Sommer J, Howerton R, Mishra G, Levine E, McQuellon R. Aprepitant/5HT-3 antagonist (EMEND) for the prevention of chemoradiation-induced nausea and vomiting (CRINV) in patients receiving gemcitabine/5-FU-based chemoradiation and concurrent upper abdominal radiation for pancreatic cancer [abstract]. J Clin Oncol. 2009;27(Suppl):e20661.

Lally BE, Urbanic JJ, Blackstock AW. Could it be that less is more? [editorial]. Lancet Oncol. 2009;10(5):435-437.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Radiation Oncology

Clinical Interests

Lung Cancer, Pancreatic Cancer
Arthur W. Blackstock Jr, M.D.

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.9
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.9
CP spoke using clear language
4.9
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.9
Patients' confidence in CP
4.9
Time CP spent with patient
4.8
Wait time at clinic
4.6



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

3/2/2016

*Dr. Blackstock & *Dr. Farris were outstanding in gathering information and then presenting their recommendations on my condition - they are very knowledgeable and professional.

1/25/2016

I had a good experience

1/6/2016

Excellent care!!!

1/6/2016

Dr. was WONDERFUL....very personable and made us feel at ease!

11/10/2015

The best.

10/29/2015

The doctor allowed most communication to be provided, by his resident. His resident informed me that a medication would be prescribed but the doctor didn't explain it's purpose or discuss it with me.

10/15/2015

All good.

10/6/2015

*Dr. Blackstock is a very good doctor. He cares about his patients.

9/27/2015

he is very compassionate and mindful of not keeping patients waiting

9/21/2015

*Dr. Blackstone is a physician who cares and provides top quality care.

7/29/2015

Great care was given.

7/27/2015

Dr. Blackstock was covering for Dr. Brown who was out of the office unexpectedly and he was absolutely wonderful. It was a conversation about your care and condition rather than feeling it was just a visit to be done.

7/6/2015

Professional, open, honest, friendly.

6/30/2015

nurses are wonderful!!!!!

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.